Prenumeration
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Delivering effective treatment to aggressive brain tumours is one of the toughest challenges in oncology. Curasight has now reported preliminary phase I data for its therapy candidate uTREAT®, providing important evidence that the company's targeted radiotherapy approach is working as intended. The early results demonstrated high tumour uptake and a favourable safety profile providing important clinical validation of the company's targeted approach. BioStock contacted CEO Ulrich Krasilnikoff for a comment.
Read the full interview at biostock.se:
Curasight reports promising early preliminary uTREAT phase I data
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/